Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
出版年份 2019 全文链接
标题
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
作者
关键词
-
出版物
OncoImmunology
Volume -, Issue -, Pages 1-13
出版商
Informa UK Limited
发表日期
2019-01-23
DOI
10.1080/2162402x.2018.1564505
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-small-cell Lung Cancer
- (2018) Yoshikane Yamauchi et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
- (2017) Etienne Giroux Leprieur et al. EUROPEAN JOURNAL OF CANCER
- Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma
- (2017) Sun Hye Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
- (2017) Renee N. Donahue et al. Journal for ImmunoTherapy of Cancer
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
- (2016) P. F. Ferrucci et al. ANNALS OF ONCOLOGY
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer
- (2016) Raffaele Califano et al. Current Oncology Reports
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy
- (2016) Rikke B. Holmgaard et al. OncoImmunology
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
- (2016) Claud Grigg et al. Journal for ImmunoTherapy of Cancer
- Unknown
- (2016) CANCER
- Colorectal Cancer Survivorship Care Guidelines
- (2015) CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Flow cytometric detection of circulating dendritic cells in healthy subjects
- (2015) B Rovati et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
- (2014) G. T. Gibney et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- (2013) J. Delyon et al. ANNALS OF ONCOLOGY
- OMIP-017: Human CD4+helper T-cell subsets including follicular helper cells
- (2013) Yolanda D. Mahnke et al. CYTOMETRY PART A
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells
- (2013) Amandine Legat et al. Frontiers in Immunology
- SPICE: Exploration and analysis of post-cytometric complex multivariate datasets
- (2011) Mario Roederer et al. CYTOMETRY PART A
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started